F-star Therapeutics, Inc. Common Stock
FSTX
FSTX was delisted on the 8th of March, 2023.
53 hedge funds and large institutions have $45.1M invested in F-star Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 8 closing their positions.
163% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 8
55% more capital invested
Capital invested by funds: $29M → $45.1M (+$16M)
33% more funds holding
Funds holding: 40 → 53 (+13)
10% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 10
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
85% less call options, than puts
Call options by funds: $272K | Put options by funds: $1.84M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$979K |
| 2 |
Wells Fargo
San Francisco,
California
|
+$723K |
| 3 |
GF
Gabelli Funds
Rye,
New York
|
+$569K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$498K |
| 5 |
GCIA
Gabelli & Co Investment Advisers
Rye,
New York
|
+$389K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.19M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.55M |
| 3 |
Russell Investments Group
London,
United Kingdom
|
-$764K |
| 4 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$658K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$606K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CC
51
Cannell Capital
Alta,
Wyoming
| $11K | +$6.08K | +1,804 | New |
|
52
JP Morgan Chase
New York
| $9K | -$66.8K | -19,837 | -93% |
|
|
TWA
53
TCI Wealth Advisors
Tucson,
Arizona
| $2K | – | – | – |
|
|
54
Adage Capital Partners
Boston,
Massachusetts
| – | -$3.19M | -900,000 | Closed |
|
|
AFM
55
Anson Funds Management
Dallas,
Texas
| – | -$658K | -185,261 | Closed |
|
56
Millennium Management
New York
| – | -$305K | -85,834 | Closed |
|
57
D.E. Shaw & Co
New York
| – | -$56K | -15,865 | Closed |
|
58
Marshall Wace
London,
United Kingdom
| – | -$37K | -10,456 | Closed |
|
|
TRCT
59
Tower Research Capital (TRC)
New York
| – | -$11K | -3,065 | Closed |
|
60
Bank of America
Charlotte,
North Carolina
| – | -$1K | -162 | Closed |
|
FSTX Hedge Fund Activity: Q2 2022 in Review
53 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q2 2022, worth a combined $45.1M — up 55% from $29M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new FSTX positions and 8 closed out — a net gain of 13 holders — while 11 added to existing stakes and 10 trimmed.
The largest buyer was Vanguard Group, adding an estimated $979K. The largest seller was Adage Capital Partners, exiting entirely with an estimated $3.19M sold.
- 53 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q2 2022, up from 40 in Q1 2022.
- Funds reported $45.1M of F-star Therapeutics, Inc. Common Stock stock for Q2 2022, up 55% quarter-over-quarter.
- 21 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q2 2022 and 8 closed out, a net change of +13 holders.
- The largest F-star Therapeutics, Inc. Common Stock buyer in Q2 2022 was Vanguard Group, an estimated $979K added.
- The largest F-star Therapeutics, Inc. Common Stock seller in Q2 2022 was Adage Capital Partners, an estimated $3.19M sold.
Based on aggregated 13F filings for Q2 2022.